StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Monday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TherapeuticsMD stock opened at $1.55 on Monday. TherapeuticsMD has a twelve month low of $1.43 and a twelve month high of $3.07. The business has a 50-day moving average price of $1.69 and a 200-day moving average price of $1.81.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter.

Institutional Trading of TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC purchased a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.